I’ve been thinking the exact same thing. My amateur analysis is that the market is still too small and soft, and it’s developing slowly. This is also signaled by the weak revenue growth. If that’s the case, then especially in terms of the stock’s valuation, the negative cash flow is a major issue. Perhaps the short-term return potential lies more in being an acquisition target for a larger healthcare operator?
4 Likes